[8-K] Dermata Therapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

Dermata Therapeutics, Inc. furnished an 8-K announcing a press release with a corporate update and financial results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1, titled “Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results.”

The information under Item 2.02 and Exhibit 99.1 is furnished, not deemed filed under Section 18 of the Exchange Act, and is not incorporated by reference unless expressly stated.

false 0001853816 0001853816 2025-11-14 2025-11-14 0001853816 DRMA:CommonStockParValue0.0001PerShareMember 2025-11-14 2025-11-14 0001853816 DRMA:WarrantsExercisableForOneShareOfCommonStockMember 2025-11-14 2025-11-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 14, 2025

Dermata Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-40739		86-3218736
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

3525 Del Mar Heights Rd., #322 San Diego, CA		92130
(Address of principal executive offices)		(Zip Code)

(858) 800-2543

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class:		Trading Symbol		Name of Each Exchange on which Registered
Common Stock, par value $0.0001 per share		DRMA		The Nasdaq Capital Market
Warrants, exercisable for one share of Common Stock		DRMAW		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 2.02. Results of Operations and Financial Condition.

On November 14, 2025, Dermata Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding its results of operations for the quarter ended September 30, 2025. A copy of the press release is furnished under Item 2.02 as Exhibit 99.1.

The information included in this Item 2.02 and Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed “filed” for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934 as amended (the “Exchange Act”). Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act made after the date hereof, the information contained in this Item 2.02 and Exhibit 99.1 hereto shall not be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 7.01. Regulation FD Disclosure.

See “Item 2.02 Results of Operations and Financial Condition” above.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated November 14, 2025, issued by Dermata Therapeutics, Inc. entitled “Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results.”
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	DERMATA THERAPEUTICS, INC.
Dated: November 14, 2025	By:	/s/ Gerald T. Proehl
		Gerald T. Proehl
		Chief Executive Officer

FAQ

What did Dermata Therapeutics (DRMA) announce in this 8-K?

The company furnished a press release with a corporate update and financial results for the quarter ended September 30, 2025, as Exhibit 99.1.

Where can I find Dermata’s Q3 2025 results details?

Details are in the press release attached as Exhibit 99.1 titled “Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results.”

Is the information considered filed or furnished?

It is furnished under Item 2.02 and not deemed filed under Section 18 of the Exchange Act, nor incorporated by reference unless expressly stated.

What items are included in the 8-K?

Item 2.02 Results of Operations and Financial Condition and Item 7.01 Regulation FD Disclosure referencing the same press release.

What is the date of the press release and report?

Both are dated November 14, 2025.

What are Dermata’s trading symbols and exchange?

Common Stock DRMA and Warrants DRMAW, both on The Nasdaq Capital Market.